NEW YORK (GenomeWeb) – OpGen reported after the opening of the market on Wednesday an 18 percent increase in its fourth quarter revenues.

For the three months ended Dec. 31, the Gaithersburg, Maryland-based infectious disease testing and analysis firm reported $1.3 million in revenues, up from $1.1 million in the prior-year Q4.

Product sales increased 220 percent to $1.3 million, attributable to the firm's acquisition of AdvanDx in July.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

23andMe's Anne Wojcicki ponders DNA and what it means to be human in a New York Times essay.

A new estimate places the last universal common ancestor to life on Earth as living 3.9 billion years ago, Inverse reports.

In PNAS this week: retinitis pigmentosa gene therapy, role of microbiome in growth stunting, and more.

Bloomberg reports that researchers and drug companies are modeling anti-obesity treatments after the rare genetic condition essential fructosuria.